Then (1954), The Doors of Perception
Mystical Experience as Therapeutic Mechanism: Huxley's Intuition Becomes Clinical Protocol
Huxley argued that the mescaline experience produced genuine mystical states, encounters with the Ground of Being, the 'is-ness' of things, that were the same as what the great mystics described. He did not frame this therapeutically; his argument was spiritual and philosophical. But his claim, that the drug reliably produces the mystical experience, was the precondition for any therapeutic claim that followed.
confirmed
The Johns Hopkins psilocybin studies (Griffiths et al., 2006, 2016; Davis et al., 2021) and the NYU studies (Bossis et al., 2015) made the MEQ30 (Mystical Experience Questionnaire) a widely used predictor of therapeutic outcomes. Mystical experience scores are associated with the size of improvements in several trials; this is a correlation, not proof that the experience causes the benefit. Griffiths et al. (2016) reported that mystical experience scores were associated with better 6-month outcomes. A specific correlation figure often quoted here (r=0.72) could not be found in the paper (Source not found; under review). Whether the Phase 3 psilocybin trials (2025 to 2026) confirmed this pattern has not been checked (Source not found; under review). Huxley's 1954 claim that the drug reliably produces mystical experience is now the primary mechanistic hypothesis in FDA-regulated clinical trials.
Sources
- Griffiths et al., Psychopharmacology (2006)
- Griffiths et al., J Psychopharmacol (2016)
- Industry Phase 3 psilocybin trial (2026)
- Davis et al., J. Psychopharmacol. 34(9):1008-1020 (2020)